Clinical Utility of Tetramer-Based Immune Monitoring in Allogeneic Stem Cell Transplantation

BioDrugs

Volumn 17, Issue 5, 2003, Pages 325-338

  Gratama, Jan W ^a   Cornelissen, Jan J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; B LYMPHOCYTE ANTIBODY; CD20 MONOCLONAL ANTIBODY; CD21 MONOCLONAL ANTIBODY; CD24 MONOCLONAL ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYTOKINE; CYTOTOXIC AGENT; EPITOPE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; RITUXIMAB; TETRAMER; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; ANTIGEN SPECIFICITY; BACTERIAL INFECTION; CELL REGENERATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DEPLETION; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOXICITY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HELPER CELL; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNOASSAY; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TECHNIQUE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; INFECTION CONTROL; INFECTION RISK; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOPROLIFERATIVE DISEASE; LYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MYCOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; REVIEW; STAINING; STANDARDIZATION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION; WHOLE BODY RADIATION;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MONITORING, IMMUNOLOGIC; STAINING AND LABELING; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0142122960     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317050-00003     Document Type: Review

References (105)

1. Maier B, Buhring HJ, Simon M, et al. Limiting dilution analysis of proliferating and helper T cells in the in vivo immune response to KLH: derepression of helper T cells at moderately increased frequencies. J Mol Cell Immunol 1986; 2 (5): 293-305
2. Owen JA, Allouche M, Doherty PC. Limiting dilution analysis of the specificity of influenza-immune cytotoxic T cells. Cell Immunol 1982 Feb; 67 (1): 49-59
3. + T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996 May 27; 191 (2): 131-42
4. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997 Apr 1; 99 (7): 1739-50
5. Matsui K, Boniface JJ, Reay PA, et al. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science 1991 Dec 20; 254 (6039): 1788-91
6. Altman J, Moss PAH, Goulder P, et al. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science 1996; 274: 94-6
7. + T cells proliferating in response to influenza A antigen. J Clin Invest 1999 Dec; 104 (12): R63-7
8. Hanke T, Takizawa H, McMahon CW, et al. Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 1999 Jul; 11 (1): 67-77
9. Matsuda JL, Naidenko OV, Gapin L, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000 Sep 4; 192 (5): 741-54
10. Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. J Immunol 2002 Aug 1; 169 (3): 1236-40
11. Mandy FF, Bergeron M, Recktenwald D, et al. A simultaneous three-color T cell subsets analysis with single laser flow cytometers using T cell gating protocol. J Immunol Methods 1992 Dec 8; 156 (2): 151-62
12. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001 Sep 1; 98 (5): 1358-64
13. Schnizlein-Bick CT, Spritzler J, Wilkening CL, et al. Evaluation of TruCount absolute-count tubes for determining CD4 and CD8 cell numbers in human immunodeficiency virus-positive adults: Site Investigators and the NIAID DAIDS New Technologies Evaluation Group. Clin Diagn Lab Immunol 2000 May; 7 (3): 336-43
14. Reimann KA, O'Gorman MR, Spritzler J, et al. Multisite comparison of CD4 and CD8 T-lymphocyte counting by single- versus multiple-platform methodologies: evaluation of Beckman Coulter flow-count fluorospheres and the tetraONE system. Clin Diagn Lab Immunol 2000 May; 7 (3): 344-51
15. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998 May 4; 187 (9): 1395-402
16. + T cells specific for EBV in healthy virus carriers. J Immunol 1999 Feb 1; 162 (3): 1827-35
17. + T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002 Apr 1; 195 (7): 893-905
18. + T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 2000 Jun 15; 69 (11): 2243-50
19. + cytotoxic T-lymphocytes in liver transplant recipients. Transplantation 2000 Jun 15; 69 (11): 2251-9
20. + T lymphocytes in healthy seropositive donors. J Virol 2000 Sep; 74 (17): 8140-50
21. + T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000 Jul 3; 192 (1): 63-75
22. + T-cell expansions: evidence for impaired CTL effector function. Eur J Immunol 2001 Mar; 31 (3): 677-86
23. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999 May 11; 96 (10): 5692-7
24. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002 Mar-Apr; 25 (21): 97-138
25. Yee C. Adoptive T cell therapy: immune monitoring and MHC multimers. Clin Immunol 2003 Jan; 106 (1): 5-9
26. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996 Nov; 70 (11): 7569-79
27. + virus-specific cytotoxic T lymphocytes. J Med Virol 1994 May; 43 (11): 103-10
28. Boppana SB, Britt WJ. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 1996 Aug 1; 222 (1): 293-6
29. + T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999 Oct; 73 (10): 8179-84
30. Longmate J, York J, La Rosa C, et al. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001; 52 (3-4): 165-73
31. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Philadelphia (PA): Lippincott-Raven Press, 1996: 2397-446
32. Aubert G, Hassan-Walker AF, Madrigal JA, et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001 Oct 15; 184 (8): 955-63
33. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001 Mar 1; 97 (5): 1232-40
34. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002 Jun 1; 99 (11): 3916-22
35. + T cells. Blood 2002 Nov 5; 100 (10): 3690-7
36. + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003 Jun 1; 101 (11): 4290-7
37. Marshall NA, Howe JG, Formica R, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000 Oct 15; 96 (8): 2814-21
38. Kwok WW, Liu AW, Novak EJ, et al. HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells. J Immunol 2000 Apr 15; 164 (8): 4244-9
39. Kwok WW. Challenges in staining T cells using HLA class II tetramers. Clin Immunol 2003 Jan; 106 (1): 23-8
40. Meyer AL, Trollmo C, Crawford F, et al. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci U S A 2000 Oct 10; 97 (21): 11433-8
41. Liu CP, Jiang K, Wu CH, et al. Detection of glutamic acid decarboxylase-activated T cells with I-Ag7 tetramers. Proc Natl Acad Sci U S A 2000 Dec 19; 97 (26): 14596-601
42. Quarsten H, McAdam SN, Jensen T, et al. Staining of celiac disease-relevant T cells by peptide-DQ2 multimers. J Immunol 2001 Nov 1; 167 (91): 4861-8
43. Buckner JH, Van Landeghen M, Kwok WW, et al. Identification of type II collagen peptide 261-273-specific T cell clones in a patient with relapsing polychondritis. Arthritis Rheum 2002 Jan; 46 (1): 238-44
44. Engleman EG, Fong L. Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients. Clin Immunol 2003 Jan; 106 (1): 10-5
45. Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. 2nd ed. Malden (MA): Blackwell Science, 1999
46. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic stem cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001 Jun 1; 97 (11): 3390-400
47. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003 Feb 15; 101 (4): 1620-9
48. + cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 1999 Jan 1; 93 (1): 394-8
49. Reddehase MJ, Weiland F, Munch K, et al. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 1985 Aug; 55 (2): 264-73
50. Quinnan Jr GV, Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982 Jul 1; 307 (1): 7-13
51. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002 Mar 15; 99 (6): 1978-85
52. Boeckh MJ. Ljungman P. Cytomegalovirus infection after BMT. In: Bowden RA, Ljungman P, Paya CV, editors. Transplant infections. Philadelphia (PA): Lippincott-Raven, 1998: 215-27
53. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993 Feb 1; 118 (3): 173-8
54. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med 1993 Feb 1; 118 (3): 179-84
55. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996 Nov 15; 88 (10): 4063-71
56. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: The City of Hope-Standford-Syntex CMV Study Group. N Engl J Med 1991 Apr 11; 324 (15): 1005-11
57. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991 Dec 5; 325 (23): 1601-7
58. Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based pre-emptive therapy for CMV infection. Bone Marrow Transplant 2000 Apr; 25 (7): 757-63
59. Zaia JA, Gallez-Hawkins GM, Tegtmeier BR, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997 Sep; 176 (3): 782-5
60. Van Esser JW, Van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001 Aug 15; 98 (4): 972-8
61. Gratama JW, Lennette ET, Lonnqvist B, et al. Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients. J Med Virol 1992 May; 37 (1): 39-47
62. Gratama JW, Oosterveer MAP, Zwaan FE, et al. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A 1988 Nov; 85 (22): 8693-6
63. Gratama JW. Epstein-Barr virus infections in bone marrow transplantation recipients. In: Forman SJ, Blume KG, Thomas ED, editors. Bone marrow transplantation. New York: Blackwell Scientific Publications, 1994: 429-42
64. Meijer E, Dekker AW, Weersink AJ, et al. Presentation and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants. Br J Haematol 2002 Dec; 119 (3): 596-607
65. Loren AW, Porter DL, Stadtmauer EA, et al. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003 Feb; 31 (3): 145-55
66. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, et al. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of post-transplant lymphoproliferative disorder. J Infect Dis 1992 Nov; 166 (5): 986-94
67. Cantarovich M, Barkun JS, Forbes RD, et al. Successful treatment of post-transplant lymphoproliferative disorder with interferon-alpha and intravenous immunoglobulin. Clin Transplant 1998 Apr; 12 (2): 109-15
68. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998 Nov; 92 (9): 3137-47
69. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991 May 23; 324 (21): 1451-6
70. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11 Suppl. 1: 113-6
71. Kuehnle I, Huls HM, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000 Feb 15; 95 (4): 1502-5
72. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001 Oct; 115 (1): 112-8
73. Van Esser JW, Niesters HG, Thijsen SF, et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001 Jun; 113 (3): 814-21
74. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation. N Engl J Med 1994 Apr 28; 330 (17): 1185-91
75. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995 Jan 7; 345 (8941): 9-13
76. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998 Sep 1; 92 (5): 1549-55
77. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000 Feb 1: 95 (3): 807-14
78. Van Esser JW, Niesters HG, Van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002 Feb 1; 99 (12): 4364-9
79. Friedrich W, O'Reilly RJ, Koziner B, et al. T-lymphocyte reconstitution in recipients of bone marrow transplants with and without GVHD: imbalances of T-cell subpopulations having unique regulatory and cognitive functions. Blood 1982 Apr; 59 (4): 696-701
80. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987 Feb; 69 (2): 369-80
81. Keever CA, Small TN, Flomenberg N, et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 1989 Apr; 73 (5): 1340-50
82. Storek J, Dawson MA. Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001 Jun; 97 (1): 3380-9
83. + selected grafts with recipients of unmanipulated grafts. Exp Hematol 1999 Mar; 27 (3): 561-8
84. Duval M, Pedron B, Rohrlich P, et al. Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. Bone Marrow Transplant 2002 Oct; 30 (7): 421-6
85. Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood 2000 Sep 15; 96 (6): 2299-303
86. Storek J, Gooley T, Witherspoon RP, et al. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997 Feb; 54 (2): 131-8
87. Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999 Jan 15; 93 (2): 467-80
88. Maury S, Mary JY, Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol 2001 Dec; 115 (3): 630-41
89. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003 Jan 15; 101 (2): 407-14
90. + T lymphocytes correlate with the occurrence of acute graft-versus-host disease. Blood 1984 Jun; 63 (6): 1416-23
91. Würsch AM, Gratama JW, Middeldorp JM, et al. The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantation. Clin Exp Immunol 1985 Nov; 62 (2): 278-87
92. + T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. Br J Haematol 1995 Jun; 90 (2): 300-7
93. Reusser P, Riddell SR, Meyers JD, et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991 Sep 1; 78 (5): 1373-80
94. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994 Apr 1; 83 (7): 1971-9
95. Krause H, Hebart H, Jahn G, et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997 Jun; 19 (11): 1111-6
96. Ljungman P, Aschan J, Azinge JN, et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol 1993 Jan; 83 (1): 118-24
97. Hebart H, Daginik S. Stevanovic S, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002 May; 99 (10): 3830-7
98. Brocrs AE, Van der Holt B, Van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000 Apr 1; 95 (7): 2240-5
99. + T lymphocytes in allogeneic stem cell transplantation. Clin Immunol 2003 Jan; 106 (1): 29-35
100. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995 Oct 19; 333 (16): 1038-44
101. Crawford DH, Mulholland N, Iliescu V, et al. Epstein-Barr virus infection and immunity in bone marrow transplant recipients. Transplantation 1986 Jul; 42 (1): 50-4
102. Lucas KG, Small TN, Heller G, et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996 Mar 15; 87 (6): 2594-603
103. + T-cell frequencies by flow cytometry. Blood 1999 Nov 1; 94 (9): 3094-100
104. Crucian BE, Stowe RP, Pierson DL, et al. Routine detection of Epstein-Barr virus specific T-cells in the peripheral blood by flow cytometry. J Immunol Methods 2001 Jan 1; 247 (1-2): 35-47
105. Kern F, Faulhaber N, Frömmel C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000 Jun; 30 (6): 1676-82